Summary & Overview
HCPCS J0720: Injection of Chloramphenicol Sodium Succinate, up to 1 gm
HCPCS Level II code J0720 identifies the injection of chloramphenicol sodium succinate, up to 1 gram. Nationally, this code is relevant for billing parenteral antibiotic therapy in acute care settings, where chloramphenicol is used for specific infections or when alternative agents are unsuitable. Accurate coding of injectable antimicrobials affects facility and professional billing, inventory tracking, and antimicrobial stewardship documentation.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, reimbursement benchmarks, and common billing considerations tied to HCPCS medication codes. The publication also provides clinical context about the service type and typical sites of service, and flags areas where policy updates or payer-specific rules commonly appear.
This summary equips billing managers, clinicians, and revenue-cycle professionals with concise information on code usage, expected settings for administration, and the types of benchmarking and policy information included in the full report. Data not available in the input will be noted explicitly in relevant sections.
Billing Code Overview
HCPCS Level II code J0720 denotes an injection of chloramphenicol sodium succinate, up to 1 gm. This code represents a parenteral antibiotic administration typically used for systemic treatment when chloramphenicol is indicated.
-
Service type: Injection/infusion medication administration
-
Typical site of service: Hospital inpatient, hospital outpatient, emergency department, or other acute care settings where intravenous or intramuscular antibiotics are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient infusion clinic or hospital inpatient unit with a severe gram-negative or mixed bacterial infection where parenteral chloramphenicol sodium succinate is clinically indicated and alternative agents are contraindicated (for example, documented severe allergy to beta-lactams and aminoglycosides, or pathogens only susceptible to chloramphenicol). The patient is typically an adult or pediatric patient requiring intravenous antibiotic therapy.
A typical workflow: the admitting clinician documents the infection diagnosis and orders J0720 (Injection, chloramphenicol sodium succinate, up to 1 gm) with dose and frequency. Pharmacy prepares the medication under sterile technique, performs dosage calculations and verifies allergies and concurrent medications. Nursing obtains IV access, verifies the order and patient identity, administers the dose per facility protocol, monitors for adverse reactions (including bone marrow suppression and aplastic anemia risk), and documents administration in the medical record. For outpatient settings, billing is submitted to the patient’s payor with appropriate modifiers reflecting the service circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Office or other outpatient service | Use when J0720 is administered in an office or outpatient infusion clinic. |